Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Guggenheim cut the pharma giant to Neutral from Buy after enrollment in two HIV-treatment trials were paused.

Merck Stock Sinks as Analyst Sees It Going Nowhere Fast

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities

Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities

After the external data monitoring committee's recommendation, Merck & Co Inc (NYSE: MRK) has paused in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591-024) Phase 3 studies evaluating islatravir (ISL) for pre-exposure prophylaxis (PrEP) in people at high risk of HIV-1 infection. Merck will conduct further analyses of these and other ongoing studies.

Merck Stops Enrollment In Two Islatravir Trials For Prevention Of HIV Infection

Salesforce

Verizon

Growth, value, and income investors all have a stock that's ripe for the picking.

3 Dow Stocks Begging to Be Bought in December

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational Oral Islatravir for Pre-Exposure Prophylaxis of HIV-1 infection

Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection

Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.

Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use

Automatic Data Processing

Becton, Dickinson and Co.

CME Group

Ecolab

Gilead Sciences

Intercontinental Exchange

Public Service Enterprise Group

T. Rowe Price Group

Travelers

Walmart

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: December 12-20, 2021

Merck & Co Inc (NYSE: MRK) has entered into a Supply Agreement with the Government of Canada for up to 1 million patient courses of molnupiravir for COVID-19.  In collaboration with Ridgeback Biotherapeutics, Merck is developing the investigational COVID-19 medicine.

Canada, Merck Ink Supply Pact For 1M Doses Of Molnupiravir For COVID-19

The FDA has approved Merck & Co Inc's (NYSE: MRK) Keytruda, an anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.  Additionally, the FDA expanded the indication for Keytruda as adjuvant treatment for stage III melanoma following complete resection to include pediatric patients (12 years and older).

Merck's Keytruda Wins Eighth FDA Approval Of 2021, This Time For Adjuvant, Pediatric Melanoma Settings

Abbott Labs

Costco

Disney

Duke Energy

Home Depot

Moderna

With the omicron variant of Covid-19 already touching down in the U.S., here are the stocks to buy to inoculate your portfolio. The post 7 Stocks to Buy to Give Your Portfolio a Booster Shot appeared first on InvestorPlace.

7 Stocks to Buy to Give Your Portfolio a Booster Shot

AbbVie

Amgen

Bristol-Myers

Eli Lilly

Pfizer

Roche Holding AG

Roche is optimally diversified both in terms of geography and in terms of portfolio. Pfizer and Eli Lilly are also broadly diversified but are more U.S.-centric companies. AbbVie, but also Merck are currently over-reliant on a single drug but this appears to be priced into the stocks accordingly.

Diversify, Diversify - Concentration Risks Of Several Pharma Companies

Merck's oral coronavirus pill may not be able to compete effectively against a rival therapy.

Here's Why Merck Lost Nearly $40 Billion in Value During November

National Retail Properties

Recent headline risks have driven great dividend stocks into bargain territory. This creates a buy-the-drop opportunity before a potentially strong finish to the year.

2 Rich Dividends To Buy Before The Santa Claus Rally

American Express

Boeing

Chevron

Dow Inc

Intel

Coca-Cola

Visa

Walgreens

"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration."– Dow Jones & Co. Thirty-one Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated net gains ranged 24.29%-43.88% topped by V 12/1/21.

Dogs Of The Dow Hit December Sporting 2 To Buy

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA as Adjuvant Treatment for Adult and Pediatric (Age 12+) Patients With Stage IIB or IIC Melanoma Following Complete Resection

FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

Merck & Co. Inc. MRK, -0.83% said Friday that it has entered into an agreement to supply the Government of Canada with up to one million patient courses of its COVID-19 pill, molnupiravir, which is being developed in collaboration with Ridgeback Biotherapeutics. Earlier this week, an advisory panel recommended that the drug maker's oral antiviral treatment of COVID-19 be authorized by the U.S. Food and Drug Administration.

Merck to supply Government of Canada with up to 1 million courses molnupiravir, its COVID-19 pill

GlaxoSmithKline

Longeveron

Health care stocks seem to be in vogue again as the Omicron Covid variant spreads globally.

Hot Stocks To Buy Right Now? 3 Health Care Stocks To Know

The stock market has overreacted to the recent negative developments for Merck & Co. ( MRK , Financial), in my opinion. The ostensible cause of the recent fall in Merck's stock price is because of the less compelling efficacy data for its Covid-19 antiviral treatment as compared to data for rival Pfizer Inc. ( PFE , Financial).

Merck's Selloff Is an Overreaction

The FDA has accepted for review Bristol Myers Squibb Co's (NYSE: BMY) supplemental application seeking approval for Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent (NTD) beta-thalassemia. The FDA has set a Prescription Drug User Fee Act goal date of March 27, 2022.

Bristol Myers - Merck's Thalassemia Candidate Under FDA Priority Review

The treatment window for COVID is very narrow; this limits the value of even effective treatments. Molnupiravir effectiveness ~30%; Paxlovid seems more effective in trials, but the real world awaits.

Early Stage COVID Treatments: Merck's Molnupiravir Struggles

Novartis

As 2021 winds down, investors may want to keep an eye on several drug companies that hope to get key approvals from the Food and Drug Administration before the year is out. Among the pharmas hoping to get their treatments green-lighted are Argenx SE ( ARGX , Financial), Calliditas Therapeutics AB ( CALT , Financial), Merck & Co. Inc. ( MRK , Financial) and Novartis ( NVS , Financial).

Merck, Novartis in Line for Key FDA Approvals This Month

Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.

Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review

Merck & Co., Inc. (MRK) Management on 4th Annual Evercore ISI HealthCONx Virtual Conference (Transcript)

Just a few days back we discussed that the stock price of Merck is being weighed down due to concerns around its Covid-19 antiviral pill - Molnupiravir - which has an efficacy of 30% against hospitalization and death in high-risk patients. Yesterday, a panel of advisors to the U.S. FDA voted in.

What's Next For Merck Stock After FDA Advisors Back Its Covid-19 Pill?

Members of U.S. Congress are free to buy and sell stocks as long as the moves are disclosed within 45 days of the transaction. This practice has been controversial over the years, with members of Congress who make decisions on key policies and department spending often having an inside line on companies that could benefit.

News for Merck Stock (MRK)